I too hope the capital raise is attractively priced - and that it is a rights issue and not a placement. Need to lower my average buy-in price. Interesting the downgrade quoted EBITDA on this occasion. On review of past announcements guidance has been in regard to NPAT or NOPAT. Does this signal further impairments?
I too hope the capital raise is attractively priced - and that...
-
- There are more pages in this discussion • 164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
